Special Drug Use Investigation of EYLEA for Diabetic Macular Edema

Status Completed

Clinical Trial Summary

The objectives of this study are to investigate the safety and effectiveness of EYLEA

Clinical Trial Description

This is a prospective, non-interventional, multi center post-authorization safety study that includes patients with a diagnosis of myopic choroidal neovascularization. The investigator will have made the choice of treatment (EYLEA) as well as the decision to use EYLEA according the Japanese Package Insert prior to enrolling the patient in this study. The observation period for each patient starts when therapy with EYLEA is initiated. The enrollment period is 2 years. Patients will be followed for a time period of 2 years or until it is no longer possible (e.g. lost to follow-up) within the 2 years. In total, 600 patients will be recruited. For each patient, data are collected as defined in the electronic case report form (eCRF) at the initial visit, follow-up visits and final visit, either by routine clinical visits (as per investigators routine practice). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02425501
Study type	Observational
Source	Bayer
Contact
Status	Completed
Phase
Start date	January 20, 2015
Completion date	August 13, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04292912` - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2798745 in Participants With Diabetic Macular Edema	Phase 1
Recruiting	`NCT05976139` - Micropulsed Laser in Patients With Macular Oedema in Retinal Dystrophies	N/A
Completed	`NCT03660371` - ILM Peeling in PDR Patients Undergoing PPV for VH	N/A
Completed	`NCT03660345` - PPV With Internal Limiting Membrane Peeling for Treatment-Naïve DME	Phase 3
Completed	`NCT01660802` - Safety and Efficacy Study of Dexamethasone in the Treatment of Patients With Macular Edema Following Retinal Vein Occlusion (RVO)	Phase 3
Completed	`NCT01908816` - An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases.	Phase 3
Completed	`NCT04592419` - A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)	Phase 3
Completed	`NCT02867735` - A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Macular Edema	Phase 1
Completed	`NCT02623673` - Simultaneous Therapy With Intravitreal Dexamethasone Implant and Bevacizumab for the Treatment of Macular Edema	N/A
Terminated	`NCT01946399` - Ozurdex Implant for Macular Edema After Treatment Failure With Anti-VEGF	N/A
Completed	`NCT01428388` - Bevacizumab Versus Ranibizumab in Treatment of Macular Edema From Vein Occlusion	N/A
Completed	`NCT01231633` - Comparison of Initial Ozurdex (Dexamethasone Implant) to Avastin (Bevacizumab) for Treatment of Macular Edema Caused by Central Retinal Vein Occlusion (CRVO)	N/A
Recruiting	`NCT01023113` - To Compare Visual Field Impairment in Conventional Double Frequency Nd: YAG Panretinal Photocoagulation With PASCAL Panretinal Photocoagulation	N/A
Terminated	`NCT00969293` - Study to Assess the Safety and Tolerability of a Single Administration of FOV2302 (Ecallantide) in Patients With Macular Edema Associated With Central Retinal Vein Occlusion	Phase 1
Completed	`NCT00970957` - Safety and Effectiveness of Bevacizumab Intravitreal Injections in the Treatment of Macular Edema Secondary to Retinal Vein Occlusion	Phase 3
Terminated	`NCT00918554` - Efficacy Study of Methotrexate to Treat Sarcoid-associated Uveitis	Phase 4
Completed	`NCT00476593` - Retinal OCT and (mfERG) Related to Age, Sex, and the Use of Anti-inflammatory Medications	N/A
Completed	`NCT00411970` - 20- Versus 23- Gauge System for Pars Plana Vitrectomy	Phase 4
Completed	`NCT00668239` - Diffuse Diabetic Maculopathy With Intravitreal Triamcinolone or Laser	N/A
Terminated	`NCT01939691` - Macular Edema Nepafenac vs. Difluprednate Uveitis Trial	Phase 4